# Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera

Source: https://onco.cc/trials/nct07891533/  
OnCo record `nct07891533` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Epetraborole run by AN2 Therapeutics, Inc, not yet recruiting.

## Summary

Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera is a phase 2 interventional study registered as NCT07891533 by AN2 Therapeutics, Inc, with 75 participants planned, started 2026-11, primary completion expected 2029-04. Conditions recorded: Polycythemia Vera (SNOMED CT: 109992005). Interventions recorded: Epetraborole, Placebo.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07891533
- Phase: 2
- Setting: A Phase 2 Study of the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Epetraborole Tablets for the Treatment of Adults With Phlebotomy-Dependent Polycythemia Vera
- Sponsor: AN2 Therapeutics, Inc
- Enrolled: 75

## Sources

- ClinicalTrials.gov NCT07891533: https://clinicaltrials.gov/study/NCT07891533

## Connected records

- cancers: [Polycythaemia vera (PV)](https://onco.cc/cancers/polycythaemia-vera/)
- drugs: [Epetraborole](https://onco.cc/drugs/epetraborole/)
- companies: [AN2 Therapeutics](https://onco.cc/companies/an2-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07891533.json